Biohaven Ltd. $BHVN Shares Purchased by Quantinno Capital Management LP

Quantinno Capital Management LP boosted its stake in Biohaven Ltd. (NYSE:BHVN) by 190.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 121,554 shares of the company’s stock after buying an additional 79,640 shares during the quarter. Quantinno Capital Management LP’s holdings in Biohaven were worth $1,028,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Renaissance Technologies LLC acquired a new position in shares of Biohaven during the first quarter valued at approximately $1,362,000. Sei Investments Co. boosted its stake in shares of Biohaven by 34.3% in the first quarter. Sei Investments Co. now owns 33,435 shares of the company’s stock worth $283,000 after acquiring an additional 8,538 shares during the last quarter. Swiss National Bank boosted its stake in shares of Biohaven by 12.8% in the first quarter. Swiss National Bank now owns 258,600 shares of the company’s stock worth $2,188,000 after acquiring an additional 29,400 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Biohaven by 12.9% in the first quarter. Bank of New York Mellon Corp now owns 307,244 shares of the company’s stock worth $2,599,000 after acquiring an additional 35,088 shares during the last quarter. Finally, Hsbc Holdings PLC increased its position in shares of Biohaven by 86.7% during the first quarter. Hsbc Holdings PLC now owns 45,115 shares of the company’s stock worth $379,000 after purchasing an additional 20,949 shares in the last quarter. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Biohaven Stock Performance

Shares of Biohaven stock opened at $14.66 on Friday. Biohaven Ltd. has a one year low of $7.48 and a one year high of $18.57. The company has a market cap of $2.21 billion, a price-to-earnings ratio of -3.16 and a beta of 1.26. The company has a debt-to-equity ratio of 21.23, a quick ratio of 7.41 and a current ratio of 4.73. The business’s 50 day moving average price is $14.32 and its 200 day moving average price is $11.69.

Biohaven (NYSE:BHVN) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.15). On average, research analysts predict that Biohaven Ltd. will post -3.11 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently commented on the company. Bank of America reissued an “underperform” rating and issued a $11.00 price objective (down from $12.00) on shares of Biohaven in a research note on Monday, June 29th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Biohaven in a report on Friday, June 26th. HC Wainwright reiterated a “neutral” rating and issued a $10.00 target price on shares of Biohaven in a research report on Tuesday, May 26th. Wall Street Zen raised shares of Biohaven from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 27th. Finally, Royal Bank Of Canada boosted their price target on shares of Biohaven from $22.00 to $23.00 and gave the stock an “outperform” rating in a research report on Tuesday. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Biohaven currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.75.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.